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OBJECTIVES We sought to determine whether hormone replacement therapy (HRT) is associated with an
improved prognosis in women with advanced heart failure (HF) and systolic dysfunction.
BACKGROUND There are about two million postmenopausal women in the U.S. with HF. However, limited
data are available to assess the effects of HRT on survival in this large group of patients.
METHODS A retrospective analysis of women age 50 years and over entered into the Beta-Blocker
Evaluation of Survival Trial (BEST) was conducted using Cox regression analysis comparing
survival in HRT users and non-users after correcting for baseline variables known to predict
survival in women with HF and systolic dysfunction.
RESULTS In 493 women age 50 years and older, HRT was associated with a significant reduction in
mortality—21% mortality in HRT users and 34% in non-users (p  0.025). Multivariate
analysis demonstrated a hazard ratio for mortality of 0.6 (95% confidence interval  0.36 to
0.97) (p  0.039) for HRT users. The benefits of HRT were noted only in women with a
nonischemic etiology of HF (n  237).
CONCLUSIONS Hormone replacement therapy is associated with a marked improvement in survival in
postmenopausal women with advanced HF. A prospective, randomized trial of HRT should
be performed in this large group of patients. (J Am Coll Cardiol 2003;42:1238–45) © 2003
by the American College of Cardiology Foundation
Heart failure (HF) is a common cause of morbidity and
mortality in both men and women. It is estimated that four
to five million people in the U.S. have HF and that one-half
of these are women (1,2). Data from the Framingham Heart
Study and the National Health and Nutrition Examination
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and Survey-I suggest that at least 70% of women with HF
are over age 50 years—the average age of menopause in the
U.S. (3,4). Thus, there are at least two million menopausal
women in the U.S. with HF. Mortality is high in women
with HF, with estimates of 50% to 90% mortality over 10
years (3,4). Despite the frequency and severity of advanced
HF in postmenopausal women, there is only one study
investigating the effect of hormone replacement therapy
(HRT) in these women. This retrospective study combined
trials comparing vesnarinone with placebo in patients with
advanced HF (5). After accounting for known predictors of
mortality, estrogen use was associated with a 32% decrease
in HF mortality. We sought to confirm whether HRT is
associated with an improved prognosis in women with
advanced HF and systolic dysfunction using data collected
in the Beta-Blocker Evaluation of Survival Trial (BEST).
METHODS
The BEST study. The BEST trial was a multicenter,
prospective, randomized trial comparing a nonselective
beta-blocker, bucindolol, with placebo in patients with New
York Heart Association (NYHA) functional class III or IV
HF and an ejection fraction of 35%. The design of this
trial and the study results have been published (6,7).
Exclusion criteria included a reversible cause of HF and
infarction within the previous six months (6). Other exclu-
sion criteria included a coronary revascularization procedure
within 60 days, patients who were candidates to be listed for
heart transplantation, unstable angina defined as uncor-
rected thyroid disease, obstructive or hypertrophic cardio-
myopathy, amyloidosis, active myocarditis, malfunctioning
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prosthetic heart valve, or myocardial use of6 nitroglycerin
tablets per week, heart rate 50 beats/min, life expectancy
of 3 years, or a serum creatinine level 3 mg/dl. Patients
with decompensated HF, pulmonary edema, or systolic
blood pressure 80 mm Hg were also excluded. Patients
were excluded if they required a drug in one of four
categories: 1) beta-adrenergic blocking agents within 30
days of baseline evaluation; 2) calcium channel blocking
agents, theophylline, tricyclic antidepressants, monoamine
oxidase inhibitors, or beta-adrenergic agonists within one
week of baseline evaluation; 3) flecainide, encainide,
propafenone, or disopyramide within two weeks of random-
ization; or 4) amiodarone within eight weeks of baseline
evaluation.
Randomization at each clinical site was stratified by
etiology of HF (ischemic or nonischemic), left ventricular
ejection fraction (LVEF) (0.20 vs. 0.20), gender, and
race. Follow-up visits occurred at 3, 6, and 12 months after
randomization and at 6-month intervals thereafter. The
primary end point was all-cause mortality. Secondary end
points included cardiovascular mortality, all-cause and con-
gestive heart failure (CHF)-specific hospitalization, the
combination of death and cardiac transplantation, LVEF at
3 and 12 months, myocardial infarction, quality of life, and
a change in the need for cotherapy.
We conducted a retrospective analysis to examine the
effect of HRT in postmenopausal women on survival and to
evaluate whether the effect varied according to etiology of
HF. We also examined HRT-by-treatment effect
(bucindolol-placebo) interactions for mortality.
Definition of postmenopausal and HRT. Women in this
trial were considered to be postmenopausal if they were50
years of age. Women were classified as using HRT if they
were taking estrogen, progestin, or a combination of both at
the baseline evaluation.
Assessment of compliance and health status. Compli-
ance to follow-up was estimated by percent attendance at
the three-month follow-up visit. Health status was esti-
mated by the prevalence of current smoking and body mass
index (BMI) at the baseline evaluation. Coronary artery
disease (CAD) was defined as the presence of significant
disease by angiography or evidence of a previous myocardial
infarction.
Statistical analysis. Means and standard deviations or
medians are reported for continuous data. Proportions are
reported for categorical data. The p values reported for the
comparisons of the HRT and non-HRT subgroups are
from the t test, except when the data were non-normal and
the Wilcoxon rank sum test for continuous variables was
used. For categorical variables the chi-square test was used,
except in cases when the expected cell counts were 5 and
the Fisher’s exact test was used. Two-sided tests of signif-
icance were performed using an alpha of 0.05. Cox propor-
tional hazards regression was used to examine the effect of
HRT on survival, adjusting for prespecified variables and to
estimate risk (hazard) ratios and corresponding confidence
intervals (CIs). A backward elimination process was used to
derive the multivariate model, which examined the follow-
ing predictors: LVEF, NYHA functional classification,
etiology of HF (ischemia  CAD, no ischemia  no
CAD), race, age, diabetes, cardiothoracic ratio (CTR),
HRT, and treatment group assignment (bucindolol or
placebo). Cox regression models were also used to examine
HRT-by-CAD and HRT-by-treatment interactions. The
model-based Kaplan-Meier curves were corrected for po-
tential confounders, including CTR, NYHA functional
classification, etiology (CAD vs. non-CAD), LVEF, and
treatment group.
RESULTS
Patient characteristics. A total of 2,708 patients were
randomized in the BEST study, including 593 women. Of
the 593 women, 435 (73%) were 50 years of age and were
considered to be postmenopausal. Subjects were considered
to be using HRT if they were taking oral or transdermal
estrogen alone, a progestin, or a combination of estrogen
and progestin. Of the 435 women age 50 years or older, 122
(23%) were using HRT. No woman age 50 years or above
was using oral contraceptives. Of the 102 HRT users, 72
were using estrogen alone, 3 were using a progestin alone,
and 27 were using a combination of the two hormones. The
baseline characteristics of the HRT users and non-HRT
users are shown in Table 1. Hormone replacement therapy
users were younger and more often non-black compared
with the HRT non-users. Hormone replacement therapy
users had a lower BMI compared with the non-HRT
subgroup, primarily because of a height difference. Hor-
mone replacement therapy users were less likely to have a
history of hypertension and diabetes than the non-users.
Systolic and diastolic blood pressure, heart rate, LVEF and
right ventricular ejection fraction, and the prevalence of
atrial fibrillation were not different between the two sub-
groups. Medications at baseline were similar, with the
exception of fewer vasodilators being taken by HRT users
compared with non-users (p  0.047). Hormone replace-
ment therapy users had slightly lower creatinine, serum
sodium, and alanine aminotransferase levels than their
non-HRT counterparts. Median plasma norepinephrine
Abbreviations and Acronyms
BMI  body mass index
CAD  coronary artery disease
CHF  congestive heart failure
CI  confidence interval
CTR  cardiothoracic ratio
HF  heart failure
HR  hazard ratio
HRT  hormone replacement therapy
LVEF  left ventricular ejection fraction
MAPK  mitogen-activated protein kinase
NYHA  New York Heart Association
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Table 1. Baseline Clinical Characteristics by HRT User Status*
Characteristics
HRT User (n  102) HRT Non-User (n  333)
Overall
P Value
Placebo
(n  49)
Bucindolol
(n  53) Overall
Placebo
(n  165)
Bucindolol
(n  168) Overall
Demographic
Age (yrs) 61.8  7.5 61.2  7.3 61.5  7.4 63.8  8.6 65.1  9.0 64.5  8.8 0.004
Range 50–78 50–77 50–78 50–86 50–93 50–93
Weight (lbs) 150.3  34.0 152.4  27.1 151.4  30.5 155.5  37.7 156.5  35.5 156.0  36.5 0.204
Height (in) 64.0  2.5 64.2  2.5 64.1  2.5 63.4  2.6 63.1  2.8 63.3  2.7 0.007
Body mass index (kg/m2) 25.9  6.2 26.1  5.1 26.0  5.6 27.1  6.0 27.6  6.2 27.4  6.1 0.048
Median duration of CHF (months) 48.0 46.0 47.5 36.0 40.5 39.0 0.178*
Range 1–240 1–288 1–288 1–199 1–456 1–456 –
Current smoker 5 (10%) 7 (13%) 12 (12%) 12 (7%) 19 (11%) 31 (9%) 0.467
Ever smoked 30 (61%) 32 (60%) 62 (61%) 83 (51%) 87 (53%) 170 (52%) 0.120
Race
White non-Hispanic 41 (84%) 47 (89%) 88 (86%) 106 (64%) 105 (63%) 211 (63%) 0.000
Black non-Hispanic 7 (14%) 5 (9%) 12 (12%) 46 (28%) 52 (31%) 98 (29%)
Hispanic or Latino 1 (2%) 1 (2%) 2 (2%) 10 (6%) 10 (6%) 20 (6%)
Other 0 (0%) 0 (0%) 0 (0%) 3 (2%) 1 (1%) 4 (1%)
NYHA functional class
III 44 (90%) 50 (94%) 94 (92%) 149 (90%) 154 (92%) 303 (91%) 0.715
IV 5 (10%) 3 (6%) 8 (8%) 16 (10%) 14 (8%) 30 (9%)
Heart failure etiology
Ischemic 17 (35%) 23 (43%) 40 (39%) 74 (45%) 84 (50%) 158 (47%) 0.144
Nonischemic 32 (65%) 30 (57%) 62 (61%) 91 (55%) 84 (50%) 175 (53%)
History of related illness
Hypertension 24 (49%) 26 (49%) 50 (49%) 99 (60%) 107 (64%) 206 (62%) 0.021
Hyperlipidemia 25 (51%) 26 (49%) 51 (50%) 81 (49%) 74 (44%) 155 (47%) 0.541
Diabetes mellitus 12 (24%) 18 (34%) 30 (29%) 72 (44%) 73 (43%) 145 (44%) 0.011
Hemodynamics/ventricular function
Heart rate (beats/min) 82.0  11.0 81.4  10.3 81.7  10.6 83.4  13.5 82.0  11.4 82.7  12.5 0.404
Blood pressure (mm Hg)
Systolic 117.4  17.1 119.8  17.5 118.7  17.3 119.0  19.0 117.9  18.7 118.5  18.8 0.771
Diastolic 70  12 71  10 71  11 70  11 69  11 69  11 0.290
LVEF (%) 24.9  6.0 24.1  7.2 24.5  6.6 24.5  7.0 24.6  7.5 24.6  7.3 0.917
RVEF (%) 40.8  14.4 39.4  12.7 40.1  13.5 37.9  14.3 36.1  14.2 37.0  14.2 0.081
Atrial fibrillation 2 (4%) 3 (6%) 5 (5%) 8 (5%) 12 (7%) 20 (6%) 0.675
Routine medications
ACE inhibitor 43 (88%) 45 (85%) 88 (86%) 147 (89%) 153 (91%) 300 (90%) 0.277
Angiotensin receptor blocker 6 (12%) 7 (13%) 13 (13%) 18 (11%) 9 (5%) 27 (8%) 0.156
Digitalis 46 (94%) 50 (94%) 96 (94%) 152 (92%) 152 (90%) 304 (91%) 0.359
Diuretic 44 (90%) 50 (94%) 94 (92%) 156 (95%) 165 (98%) 321 (96%) 0.101
Aldactone (spironolactone) 4 (8%) 2 (4%) 6 (6%) 9 (5%) 4 (2%) 13 (4%) 0.101
Vasodilator 17 (35%) 23 (43%) 40 (39%) 90 (55%) 78 (46%) 168 (50%) 0.047
Hydralazine/isosorbide 13 (27%) 18 (34%) 31 (30%) 57 (35%) 63 (38%) 120 (36%) 0.295
Antiarrhythmic 2 (4%) 0 (0%) 2 (2%) 1 (1%) 1 (1%) 2 (1%) 0.235
Anticoagulant 18 (37%) 26 (49%) 44 (43%) 63 (38%) 65 (39%) 128 (38%) 0.396
Aspirin 21 (43%) 22 (42%) 43 (42%) 70 (42%) 61 (36%) 131 (39%) 0.611
Statin lipid-lowering agents 9 (18%) 13 (25%) 22 (22%) 41 (25%) 32 (19%) 73 (22%) 0.940
Laboratory values
Creatinine (mg/dl) 1.0  0.3 1.0  0.4 1.0  0.3 1.1  0.4 1.1  0.4 1.1  0.4 0.007*
Serum sodium (mg/dl) 138.6  2.7 137.8  2.8 138.2  2.7 139.5  3.4 139.3  3.0 139.4  3.2 0.001
Serum potassium (mg/dl) 4.3  0.5 4.3  0.5 4.3  0.5 4.3  0.5 4.3  0.5 4.3  0.5 0.607
Serum ALT (mg/dl) 19.3  9.2 19.1  8.5 19.2  8.8 25.7  16.3 25.4  18.7 25.5  17.5 0.0001*
Median plasma norepinephrine (pg/ml) 392.0 423.0 420.0 460.0 423.0 441.0 0.413*
ECG/X-ray
QRS duration, (ms) 137.1  32.3 137.5  34.4 137.4  33.2 131.4  36.2 129.8  34.7 130.6  35.4 0.087
QT duration–corrected (ms) 450.6  45.7 458.7  53.0 454.8  49.6 451.9  45.8 446.0  47.6 448.9  46.7 0.273
LBBB 22 (45%) 24 (45%) 46 (45%) 60 (36%) 63 (38%) 123 (37%) 0.139
Cardio/thoracic ratio 58.6  6.6 56.6  7.6 57.6  7.2 60.4  8.0 60.2  7.2 60.3  7.6 0.002
*Mean  SD unless otherwise indicated. p Value based on Wilcoxon rank sum test.
ACE  angiotensin converting enzyme; ALT  alanine aminotransferase; CHF  congestive heart failure; ECG  electrocardiogram; HRT  hormone replacement
therapy; LBBB  left bundle blanch block; LVEF  left ventricular ejection fraction; NYHA  New York Heart Association; RVEF  right ventricular ejection fraction.
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values were not different between the two subgroups. There
were no differences in the QRS or corrected QT durations
or the incidence of left bundle branch block. Hormone
replacement therapy users had a smaller CTR compared
with non-HRT users (p  0.002).
Figure 1 depicts the model-based survival curves adjusted
for potential confounders for HRT users and non-users.
There were 134 deaths in the 435 women age 50 and over
with a mean follow-up of 2 years. Twenty-one deaths (21%)
occurred in the 102 HRT users and 113 deaths (34%) in the
333 non-HRT users. There was a significant difference in
survival favoring HRT users (Wald chi-square p value for
HRT  0.04). Table 2 presents the results from the
multivariate analysis using prespecified risk factors known to
predict mortality in patients with HF and adjusting for
treatment group assignment (bucindolol or placebo). Sig-
nificant factors predicting higher mortality included NYHA
functional class IV vs. III and an ischemic etiology of HF.
A higher LVEF and HRT use were associated with a lower
mortality. After adjusting for the effect of HRT, treatment
group assignment and etiology of CHF, we found no
significant effect of HRT-by-treatment interaction (p 
0.85) or HRT-by-etiology of CHF (CAD vs. no CAD)
interaction (p  0.09) on mortality.
Survival curves adjusted for potential confounders com-
paring HRT users with non-HRT users by etiology of
disease are presented in Figure 2. Of the 198 women with
ischemic etiology, there was no difference in survival be-
tween HRT users and non-users (HR  0.74, 95% CI 
0.41 to 1.33, Wald chi-square p value  0.31). However,
there was a significant survival benefit for HRT users in the
237 nonischemic postmenopausal women (HR 0.35, 95%
CI  0.14 to 0.87, Wald chi-square p value  0.02).
We compared the survival between unopposed estrogen
HRT users (n  72) to those users on a combination of
estrogen plus progestin (n  27). A total of 21 deaths
occurred, 15 (21%) in unopposed estrogen users and 6
(22%) in those using combination estrogen and progestin.
Figure 1. Model-based survival curves for survival by hormone replacement therapy (HRT) use in postmenopausal women. Difference between HRT
subgroups is significant. (Wald chi-square p value for HRT  0.04) Adjustment was made for etiology of disease (coronary artery disease vs. non-coronary
artery disease), cardiothoracic ratio, New York Heart Association functional classification, left ventricular ejection fraction, and treatment group. CI 
confidence interval; HR  hazard ratio.
Table 2. Multivariate Predictors of Mortality Including
Treatment Group Assignment
Covariate
Relative
Risk 95% CI p Value
NYHA (IV vs. III) 2.610 1.659–4.107 0.0001
CAD (ischemic vs. nonischemic) 2.492 1.737–3.573 0.0001
LVEF (per 1 EF unit increase) 0.961 0.935–0.988 0.0042
HRT (taking vs. not taking) 0.595 0.364–0.973 0.0387
Cardio/thoracic ratio 1.026 1.000–1.053 0.0502
Treatment (bucindolol vs. placebo) 0.710 0.502–1.005 0.0534
n  426, total deaths  131. Estimates from Cox proportional hazards regression
model. Model derived using a backwards elimination process considering the
following covariates: left ventricular ejection fraction (LVEF), New York Heart
Association (NYHA) classification, etiology of heart failure (ischemia  coronary
artery disease [CAD] or no ischemia  no CAD), race, age, diabetes, cardiothoracic
ratio, hormone replacement therapy (HRT), and treatment group assignment
(bucindolol or placebo).
CI  confidence interval; EF  ejection fraction.
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There was no difference in survival between combination
HRT and unopposed estrogen subgroups (HR 1.09, 95%
CI  0.42 to 2.82, p  0.86).
The results of the multivariate analysis including BMI
and current smoking status as measures of health status and
using attendance at the three-month visit as a measure of
compliance are presented in Table 3. The frequency of
current smoking status and the BMIs for HRT users and
non-users are shown in Table 1. Attendance at the three-
month clinic visit was 93% among both HRT users and
non-users. Forcing measures of health status and compli-
ance into the multivariate analysis resulted in an estimated
relative risk for mortality for HRT of 0.54 (95% CI  0.33
to 0.91) and p value of 0.019.
DISCUSSION
Our study suggests that the use of HRT in women with
advanced HF and systolic dysfunction is associated with a
significant survival benefit. Hormone replacement therapy
users had a number of baseline features that are known to
predict a better prognosis. These included a younger age, a
higher percentage of non-black subjects, less hypertension
and diabetes, and a higher frequency of nonischemic etiol-
ogy. When these factors are accounted for in a multivariate
analysis, HRT remains a significant predictor of mortality
with a relative risk of 0.60 (p  0.039).
Only one previous study has addressed the issue of HRT
in women with HF. Using data combined from three trials
of patients with advanced HF comparing vesnarinone with
placebo, the relative risk of HRT for survival was 0.68 (5).
The baseline characteristics in that study were similar to our
study with HRT users being younger, less often black, and
more frequently having a nonischemic etiology. In both
studies, 21% to 22% of women age 50 years and older were
using HRT. In both studies, multivariate analysis did not
alter the apparent association of HRT with survival. Our
study had a mean follow-up of two years, compared with a
mean follow-up of 1 year in the study of Reis et al. (5).
Thus, our findings confirm the study of Reis et al. (5) and
Figure 2. Model-based survival curves by hormone replacement therapy (HRT) use within etiology of disease. Differences are significant for women with
a non-coronary artery disease (CAD) etiology but not for those with a CAD etiology. Adjustment was made for cardiothoracic ratio, New York Heart
Association functional classification, left ventricular ejection fraction, and treatment group. CI  confidence interval; HR  hazard ratio.
Table 3. Multivariate Predictors of Mortality Including
Measures of Compliance and Health Status
Covariate
Relative
Risk 95% CI P Value
NYHA functional class (IV vs. III) 2.766 1.738–4.402 0.0001
CAD (ischemic vs. nonischemic) 2.171 1.494–3.155 0.0001
Compliance (yes vs. no) 0.235 0.142–0.389 0.0001
LVEF (per 1 EF unit increase) 0.952 0.925–0.980 0.0007
Current smoker (yes vs. no) 0.464 0.224–0.959 0.0381
BMI (per kg/m2) 0.970 0.939–1.003 0.0742
Cardio/thoracic ratio 1.020 0.994–1.047 0.1379
HRT (taking vs. not taking) 0.544 0.327–0.906 0.0193
Treatment (bucindolol vs. placebo) 0.697 0.489–0.994 0.0462
*Table 2 model with BMI  smoker  compliance with treatment. N  425, total
deaths  130. estimates from Cox proportional hazards regression model. Compli-
ance at three-month visit defined as a patient attending her three month visit and
having a physical exam completed.
BMI  body mass index; CAD  coronary artery disease; CI  confidence
interval; HRT  hormone replacement therapy; LVEF  left ventricular ejection
fraction; NYHA  New York Heart Association.
1242 Lindenfeld et al. JACC Vol. 42, No. 7, 2003
HRT and Heart Failure October 1, 2003:1238–45
also suggest that the association of HRT with improved
mortality in women with advanced HF is present even with
prolonged follow-up.
Hormone replacement therapy was associated with a
marked improvement in survival in women with a nonisch-
emic etiology of HF (HR  0.35, 95% CI  0.14 to 0.87,
p  0.02) but no improvement in women with an ischemic
etiology (HR  0.74, 95% CI  0.41 to 1.33, p  0.31)
(Fig. 2). This effect of etiology differs from the study of Reis
et al. (5), in which etiology of HF did not impact the benefit
of HRT. However, in that study the benefits of HRT were
not statistically significant in either ischemic or nonischemic
etiologies when the groups were considered separately. A
test of interaction of benefit of HRT by etiology had a p
value of 0.09. Although not statistically significant, this p
value certainly does not exclude the possibility of an inter-
action between etiology of CHF and HRT. Indeed, a larger
study will be necessary to be certain if etiology of HF is
important for the benefits of HRT.
We found no difference in the benefits of combination
estrogen and progestin versus unopposed estrogen. Reis et
al. (5) reported a trend for estrogen alone to be associated
with improved mortality. The small numbers of patients in
both studies do not allow firm conclusions.
Potential mechanisms of benefit of HRT. Hormone
replacement therapy may improve survival in postmeno-
pausal women with advanced HF through effects on endo-
thelial function, neurohormonal activation, myocardial re-
modeling, CAD, or any combination of these.
Postmenopausal women have impaired endothelial function
as measured by flow-mediated vasodilation (8,9). Chronic
HRT with estrogen alone or with the combination of
17-estradiol and norethisterone acetate improves
endothelial-dependent vasodilation in postmenopausal
women (9–11). Improved endothelial function may result in
lower systemic vascular resistance and improved cardiac
output in women with advanced HF, although no studies of
HRT have been conducted in postmenopausal women with
HF.
Neurohormonal activation is associated with a poorer
prognosis in patients with HF (12,13). Increasing levels of
norepinephrine, renin, angiotensin II, and endothelin have
all been correlated with poorer survival in patients with HF
(12–14). Hormone replacement therapy, particularly estro-
gen, is associated with reduced activation of a number of
neurohormonal systems. Estrogen is known to suppress
muscle sympathetic nerve activity, both at rest and after
exercise in postmenopausal women (15). It is not known if
cardiac sympathetic activity is also suppressed by estrogen,
but muscle sympathetic nerve activity is known to reflect
cardiac sympathetic activity (16). Estrogen supplementation
to perimenopausal women for eight weeks decreased systolic
and diastolic blood pressure and total body norepinephrine
spillover in response to mental stress (17). Estrogen and
progesterone decrease angiotensin-converting enzyme levels
while increasing bradykinin levels in hypertensive post-
menopausal women (18,19). Estrogen is known to decrease
endothelin levels in healthy postmenopausal women (9,11).
Thus, there is evidence that HRT might reduce activation
of a number of neurohormonal systems that are known to be
associated with increased mortality in HF. There are no
data addressing the effects of HRT on neurohormonal
activation in women with HF. However, if HRT provides
similar benefits in women with advanced HF as in healthy
postmenopausal women, an effect of HRT on mortality in
HF might be expected.
There are substantial gender differences in myocardial
remodeling due, at least in part, to the influence of sex
hormones. In the general population there is a progressive
age-related increase in myocardial mass in healthy women
that is not seen in their male counterparts (20). These
findings were confirmed in a healthy, nonobese, normoten-
sive subset of the Framingham Heart Study (21). These
studies demonstrate the increase in myocardial mass occurs
primarily in postmenopausal women. Indeed, premeno-
pausal women with essential hypertension have thinner
posterior left ventricular walls, smaller left ventricular mass,
and better cardiac function than age-matched men (22). In
one study, women using HRT for more than 10 years had
a significant reduction in septal and posterior left ventricular
wall thickness when compared with controls (23). Elderly
(postmenopausal) women with systolic hypertension or
aortic stenosis have more concentric remodeling and better
preserved left ventricular systolic function than their male
counterparts both at rest and with exercise (24–28). These
data suggest that female sex hormones, estrogen and pro-
gesterone, influence myocardial hypertrophy and myocardial
remodeling by suppressing cardiac hypertrophy and preserv-
ing myocardial function. Studies in animals subjected to a
left ventricular pressure load also demonstrate a substantial
effect of female sex hormones on myocardial remodeling.
Female rats subjected to pressure loads demonstrate less
hypertrophy than male rats (29). Furthermore, female mice
subjected to pressure overloads have less progression to HF
than do the males (29–31). Female rats demonstrate gene
expression changes in beta-myosin and sarcoplasmic retic-
ulum calcium adenosine triphosphatase expression consis-
tent with less hypertrophy and preserved systolic function
(32). It is known that estrogen receptors are present in the
myocardium (33). Recently two studies have contributed
information linking 17-estradiol with cardiac hypertrophy.
van Eickels et al. (34) have shown that 17-estradiol
reduces left ventricular hypertrophy in ovariectomized mice
subjected to aortic constriction. Estrogen therapy was asso-
ciated with reduced levels of p38 mitogen-activated protein
kinase (MAPK). The MAPK proteins are important in the
activation and maintenance of cardiac hypertrophy and
p38MAPK may be important in the progression to HF
(35). In another study, Xin et al. (36) have demonstrated
that male FKBP 12.6 knockout mice develop left ventricular
hypertrophy, whereas the female knockouts do not. FKBP
12.6 is an intracellular binding protein that modulates the
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action of the cardiac ryanodine receptor complex, which
regulates sarcoplasmic reticulum calcium release. Blocking
estradiol receptors in the female mice resulted in hypertro-
phy similar to that seen in the male mice. Thus, estrogen
may have effects on more than one pathway influencing
cardiac hypertrophy.
Myocyte apoptosis may also be important in myocardial
remodeling. Olivetti et al. (37), in an autopsy study, dem-
onstrated that myoctye number and volume are better
preserved in women than in men. This intriguing study is
supported by recent findings that estrogen may be important
in the activation of the antiapoptotic protein AKT in the
heart (38). Thus HRT, and particularly estrogen, positively
effect myocardial hypertrophy and remodeling, and this
mechanism seems the most plausible explanation for the
improved survival with HRT in women with advanced HF.
Recent studies differ about whether HRT alters the
natural history of CAD in women. Data from the Heart and
Estrogen/progestin Replacement Study (HERS) and Heart
and Estrogen/progestin Replacement Study follow-up dem-
onstrated no increase in the rate of primary coronary heart
disease events or secondary cardiovascular events with com-
bination estrogen and progesterone therapy in postmeno-
pausal women with known coronary heart disease (39,40).
However the Women’s Health Initiative (WHI) found a
HR of 1.29 for coronary heart disease with combined HRT
in healthy postmenopausal women (41). Our study did not
demonstrate any benefit of HRT on survival in women with
an ischemic etiology for HF. The absence of benefit in this
subgroup may represent the sum of the positive benefit seen
in women with a nonischemic etiology and a negative effect
on CAD, such as was noted in WHI. Both the WHI and
HERS studies have demonstrated a 2-fold risk in throm-
boembolic disease in women on combination HRT (39–
41). However, the baseline risk of thromboembolic disease
was about two-fold higher in the women with coronary
disease enrolled in HERS than in the healthy postmeno-
pausal women enrolled in WHI. In the Studies Of Left
Ventricular Dysfunction (SOLVD) trials, women with HF
had an increasing rate of thromboembolic events with
decreasing ejection fraction that was not seen in the men
(42). Most of the subjects in SOLVD had underlying
coronary disease, and it is not known if the excess in
thromboembolic events in the women in SOLVD was
related to etiology of CHF. Our results could be explained
if there were an excess risk of thromboembolic events in
women with an ischemic etiology of disease compared with
those with a nonischemic etiology. Although the test for
interaction between the effect of HRT and etiology of
disease was not statistically significant (p  0.09), the
number of women in these subgroups was small, and,
accordingly, the power to detect an interaction effect was
low.
Our results may also reflect a difference in the health
status or compliance of HRT users compared with non-
users. It is known that women who take HRT have
healthier lifestyles than do non-HRT users and that this
may be an explanation of the reported benefits of HRT in
retrospective studies (43). Furthermore, compliance bias
may have influenced our study (44,45). However, when we
attempted to correct for the “healthy subject” bias and for
compliance bias as measured by compliance to treatment
visits, the benefit of HRT was the same or even larger.
Although these adjustments are rudimentary, they do not
suggest a “healthy subject” or compliance bias in our study
participants.
We have demonstrated a significant benefit of HRT use
on survival in postmenopausal women with advanced HF. It
will be important to determine if this benefit is confirmed in
a prospective, randomized trial of HRT in postmenopausal
women with HF because there are more than two million
postmenopausal women in the U.S. with HF, and this
number will continue to increase as our population ages
(46).
Study limitations. This was a retrospective study and
menopausal status was not collected prospectively. Hor-
mone replacement therapy use was only documented at
randomization and not during follow-up. This study could
not completely address the possibility that either prevention
bias or compliance bias or other factors not controlled for
could have influenced these results, as has been suggested in
studies of HRT and CAD (43–45). Although there was no
statistically significant interaction between the effect of
HRT and etiology of disease, there was low power to detect
an interaction effect because of the small number of women
in these subgroups.
Conclusions. We have demonstrated an association of
HRT with improved survival in postmenopausal women
with advanced HF and systolic dysfunction over a follow-up
of two years. The 40% reduction in mortality is nearly
identical to the 38% reduction noted in a previous study.
Our finding that this benefit is noted in women with a
nonischemic etiology of HF requires confirmation. With
more than two million postmenopausal women with HF in
the U.S., a prospective, randomized trial evaluating the
benefits of HRT in this population, particularly those with
a nonischemic etiology of HF, would be important.
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